Market Highlights

• The RMR Group has finalized Unison Elliott Bay, a threebuilding redevelopment project in Seattle featuring 300,000 square feet (sf) of life sciences labs and research and development facilities.
• RareCyte raised $20.0 million dollars to advance its applications in cell analysis.
• Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences, a Seattlebased company specializing in innovative therapies targeting the immune synapse for treating cancer and autoimmune diseases, for $4.9 billion.

Read the full report